Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis

 

 Permissions and Reprints

Abstract

An individualized approach to identify acutely ill medical patients at increased risk of venous thromboembolism (VTE) and a low risk of bleeding to optimize the benefit and risk of extended thromboprophylaxis (ET) is needed. The International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) VTE risk score has undergone extensive external validation in medically ill patients for in-hospital use and a modified model was used in the MARINER trial of ET also incorporating an elevated D-dimer. The MAGELLAN study demonstrated efficacy with rivaroxaban but had excess bleeding. This retrospective analysis investigated whether the modified IMPROVE VTE model with an elevated D-dimer could identify a high VTE risk subgroup of patients for ET from a subpopulation of the MAGELLAN study, which was previously identified as having a lower risk of bleeding. We incorporated the modified IMPROVE VTE score using a cutoff score of 4 or more or 2 and 3 with an elevated D-dimer (>2 times the upper limit of normal) to the MAGELLAN subpopulation. In total, 56% of the patients met the high-risk criteria. In the placebo group, the total VTE event rate at Day 35 was 7.94% in the high-risk group and 2.83% for patients in the lower-risk group. A reduction in VTE was observed with rivaroxaban in the high-risk group (relative risk [RR]: 0.68, 95% confidence interval [CI]: 0.51–0.91, p = 0.008) and in the lower-risk group (RR: 0.69, 95% CI: 0.40 -1.20, p = 0.187). The modified IMPROVE VTE score with an elevated D-dimer identified a nearly threefold higher VTE risk subpopulation of patients where a significant benefit exists for ET using rivaroxaban.

Note

All authors contributed equally to the manuscript: (1) conception and design of the work, analysis and interpretation of the data; (2) drafting the work or revising it critically for important intellectual content including: Introduction, Methods, Results, Discussion; (3) final approval of the version to be published; (4) agreement to be accountable for all aspects of the work in ensuring that the questions related to the accuracy or integrity of any part.

• References

• 1 Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. ThrombHaemost 2017; 117 (09) 1662-1670
  PubMedGoogle Scholar
• 2 Miao B, Chalupadi B, Clark B. , et al. Proportion of US hospitalized medically ill patients who may qualify for extended thromboprophylaxis. Clin Appl ThrombHemost 2019; 25: 1-6
  PubMedGoogle Scholar
• 3 Cohen AT, Harrington RA, Goldhaber SZ. , et al; APEX Investigators. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375 (06) 534-544
  CrossrefPubMedGoogle Scholar
• 4 Spyropoulos AC, Lipardi C, Xu J. , et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl ThrombHemost 2019; 25: 1-9
  PubMedGoogle Scholar
• 5 Kahn SR, Lim W, Dunn AS. , et al. Prevention of VTE in nonsurgical patients. Chest 2012; 141 (2, Suppl): e195S-e226S
  CrossrefPubMedGoogle Scholar
• 6 Schünemann HJ, Cushman M, Burnett AE. , et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. Blood Adv 2018; 2 (22) 3198-3225
  CrossrefPubMedGoogle Scholar
• 7 Spyropoulos AC, Anderson Jr FA, FitzGerald G. , et al; IMPROVE Investigators. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 2011; 140 (03) 706-714
  CrossrefPubMedGoogle Scholar
• 8 Mahan CE, Liu Y, Turpie AG. , et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). ThrombHaemost 2014; 112 (04) 692-699
  PubMedGoogle Scholar
• 9 Rosenberg D, Eichorn A, Alarcon M, McCullagh L, McGinn T, Spyropoulos AC. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 3 (06) e001152
  PubMedGoogle Scholar
• 10 Greene MT, Spyropoulos AC, Chopra V. , et al. Validation of risk assessment models of venous thromboembolism in hospitalized medical patients. Am J Med 2016; 129 (09) 1001.e9-1001.e18
  CrossrefPubMedGoogle Scholar
• 11 Raskob GE, Spyropoulos AC, Zrubek J. , et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE.Design, rationale, and clinical implications. ThrombHaemost 2016; 115 (06) 1240-1248
  PubMedGoogle Scholar
• 12 Cohen AT, Spiro TE, Büller HR. , et al; MAGELLAN Investigators. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 2013; 368 (06) 513-523
  CrossrefPubMedGoogle Scholar
• 13 Cohen AT, Spiro TE, Büller HR. , et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis 2011; 31 (04) 407-416
  CrossrefPubMedGoogle Scholar
• 14 Spyropoulos AC, Ageno W, Albers GW. , et al; MARINER Investigators. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 2018; 379 (12) 1118-1127
  CrossrefPubMedGoogle Scholar
• 15 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22 (04) 719-748
  PubMedGoogle Scholar
• 16 Spyropoulos AC, McGinn T, Khorana AA. The use of weighted and scored risk assessment models for venous thromboembolism. ThrombHaemost 2012; 108 (06) 1072-1076
  PubMedGoogle Scholar
• 17 Cohen AT, Spiro TE, Spyropoulos AC. , et al; MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J ThrombHaemost 2014; 12 (04) 479-487
  CrossrefPubMedGoogle Scholar
• 18 Cohen AT, Harrington R, Goldhaber SZ. , et al. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J 2014; 167 (03) 335-341
  CrossrefPubMedGoogle Scholar
• 19 Gibson CM, Spyropoulos AC, Cohen AT. , et al. The IMPROVEDD VTE risk score: incorporation of d-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open 2017; 1 (01) e56-e65
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Huang W, Anderson FA, Spencer FA, Gallus A, Goldberg RJ. Risk-assessment models for predicting venous thromboembolism among hospitalized non-surgical patients: a systematic review. J Thromb Thrombolysis 2013; 35 (01) 67-80
  CrossrefPubMedGoogle Scholar
• 21 Piazza G, Rosenbaum EJ, Pendergast W. , et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients. Circulation 2009; 119 (16) 2196-2201
  CrossrefPubMedGoogle Scholar
• 22 Piazza G, Anderson FA, Ortel TL. , et al. Randomized trial of physician alerts for thromboprophylaxis after discharge. Am J Med 2013; 126 (05) 435-442
  CrossrefPubMedGoogle Scholar
• 23 Vaitkus PT, Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Goldhaber SZ. ; PREVENT Medical Thromboprophylaxis Study Group. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. ThrombHaemost 2005; 93 (01) 76-79
  PubMedGoogle Scholar
• 24 Kalayci A, Gibson CM, Chi G. , et al. Asymptomatic deep vein thrombosis is associated with an increased risk of death: insights from the APEX trial. ThrombHaemost 2018; 118 (12) 2046-2052
  PubMedGoogle Scholar
• 25 Raskob GE, Spyropoulos AC, Cohen AT. , et al. Increased risk of death in acutely ill medical patients with asymptomatic proximal deep vein thrombosis or symptomatic venous thromboembolism: insights from the MAGELLAN study. Blood 2019; 134 (01) 163
  CrossrefPubMedGoogle Scholar